(Q37997025)

26 August 2017

title

Impact of obesity on drug metabolism and elimination in adults and children (English)

1 reference

26 August 2017

0 references

1 reference

Margreke J E Brill

1

1 reference

26 August 2017

Jeroen Diepstraten

2

1 reference

26 August 2017

Anne van Rongen

3

1 reference

26 August 2017

Simone van Kralingen

4

1 reference

26 August 2017

John N van den Anker

5

1 reference

26 August 2017

Catherijne A J Knibbe

6

1 reference

26 August 2017

language of work or name

1 reference

1 May 2012

1 reference

Clinical Pharmacokinetics

26 August 2017

published in

1 reference

26 August 2017

volume

51

1 reference

26 August 2017

issue

5

1 reference

26 August 2017

page(s)

277-304

1 reference

Prevalence and trends in obesity among US adults, 1999-2008

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Prevalence of overweight and obesity in the United States, 1999-2004

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Prevalence of High Body Mass Index in US Children and Adolescents, 2007-2008

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Characteristics of obesity and its related disorders in China

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Global burden of obesity in 2005 and projections to 2030.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Clinical pharmacokinetics of drugs in obesity. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Effects of obesity on pharmacokinetics implications for drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Cardiopulmonary aspects of obesity in women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Obesity affects the liver - the link between adipocytes and hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Anesthesia in the obese patient: pharmacokinetic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

The obese patient in the ICU.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Increased clearance of morphine in sickle cell disease: implications for pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Implications of obesity for drug therapy: limitations and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Drug disposition in obese humans. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Dosing dilemmas in obese children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Effect of obesity on the pharmacokinetics of drugs in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Dose adjustment of anaesthetics in the morbidly obese

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

The effects of obesity on drug pharmacokinetics in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Pharmacokinetics of drugs in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

What is the best size descriptor to use for pharmacokinetic studies in the obese?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and co-morbidities

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Variable expression of CYP and Pgp genes in the human small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Cytochrome p450 and chemical toxicology

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Carbamazepine pharmacokinetics in obese and lean subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Significant weight reduction in obese subjects enhances carbamazepine elimination

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Clinical enflurane metabolism by cytochrome P450 2E1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Serum Inorganic Fluoride Levels in Obese Patients during and after Enflurane Anesthesia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Biotransformation of sevoflurane

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Serum inorganic fluoride levels in mildly obese patients during and after sevoflurane anesthesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Plasma inorganic fluoride levels with sevoflurane anesthesia in morbidly obese and nonobese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Halogenated inhalational anaesthetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Acetaminophen hepatotoxicity: the first 35 years

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Genetic differences in drug disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Developmental pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Altered xanthine oxidase and N-acetyltransferase activity in obese children

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Caffeine disposition in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Factors affecting theophylline clearances: Age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Glimepiride. A review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Glimepiride pharmacokinetics in obese versus non-obese diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Pharmacogenetic phenotyping and genotyping. Present status and future potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Pharmacokinetic drug interactions of commonly used anticancer drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Steady-state plasma pharmacokinetics of oral voriconazole in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Effect of obesity on serum amiodarone concentration in Japanese patients: population pharmacokinetic investigation by multiple trough screen analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Influence of diet and nutritional status on drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Pharmacokinetics and Metabolism of Bisoprolol Enantiomers in Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

UDP-glucuronosyltransferases and clinical drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Expression of the androgen metabolizing enzyme UGT2B15 in adipose tissue and relative expression measurement using a competitive RT-PCR method

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Metabolism and disposition of novel des-fluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Hepatic microcirculation in fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Prediction of total propofol clearance based on enzyme activities in microsomes from human kidney and liver

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Linearity of pharmacokinetics and model estimation of sufentanil.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

A comparison of the pharmacokinetics of propranolol in obese and normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Clinical Pharmacokinetics of Labetalol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Clinical Pharmacokinetics of Verapamil

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Clinical pharmacokinetics of verapamil, nifedipine and diltiazem

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Lidocaine kinetics predicted by indocyanine green clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Lidocaine disposition in obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients: derivation of dosing weight ("pharmacokinetic mass").

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Clinical Pharmacokinetics of Propranolol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

MEGX disposition in critically-ill trauma patients: subsequent assessments during the first week following trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Effect of cardiopulmonary bypass on fentanyl distribution and elimination.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Altered pharmacokinetics of paclitaxel in experimental hepatic or renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Estimating the glomerular filtration rate in obese adult patients for drug dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Combined renal effects of overweight and hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Effect of obesity on inflammatory markers and renal functions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Effect of childhood obesity and obesity-related cardiovascular risk factors on glomerular and tubular protein excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Biomarkers of impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Clinical pharmacokinetics of vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Population pharmacokinetics of daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

The effect of body weight on dalteparin pharmacokinetics. A preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine

21 January 2018

2 references

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

21 January 2018

12 December 2020

Clinical Pharmacokinetics of Procainamide

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Clinical Pharmacokinetics of Digoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Anesthetizing the obese child

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Implications for kidney disease in obese children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Potential Impact of Steatosis on Cytochrome P450 Enzymes of Human Hepatocytes Isolated from Fatty Liver Grafts

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Effects of steatosis on drug-metabolizing capability of primary human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11599410-000000000-00000

Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery

21 January 2018

1 reference

12 December 2020

The impact of obesity and disease on busulfan oral clearance in adults

1 reference

12 December 2020

The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients

1 reference

12 December 2020

Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity

1 reference

12 December 2020

Lithium pharmacokinetics in the obese

1 reference

12 December 2020

Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation*

1 reference

12 December 2020

The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics

1 reference

12 December 2020

Busulfan conjugation by glutathione S-transferases alpha, mu, and pi.

1 reference

12 December 2020

Halothane biotransformation in obese and nonobese patients.

1 reference

12 December 2020

Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen

1 reference

12 December 2020

Pharmacokinetics of sufentanil in obese patients

1 reference

12 December 2020

Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity

1 reference

12 December 2020

Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources

1 reference

12 December 2020

The Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and Triazolam

1 reference

12 December 2020

Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol.

1 reference

12 December 2020

Phenytoin disposition in obesity. Determination of loading dose

1 reference

12 December 2020

Trazodone kinetics: effect of age, gender, and obesity

1 reference

12 December 2020

Pharmacokinetics of theophylline in obesity

1 reference

12 December 2020

A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor

1 reference

12 December 2020

Inflammation, stress, and diabetes

1 reference

12 December 2020

Obesity, sex, and acetaminophen disposition

1 reference

12 December 2020

Busulfan dosing in children with BMIs ≥ 85% undergoing HSCT: a new optimal strategy

1 reference

12 December 2020

1 reference

12 December 2020

Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function

1 reference

12 December 2020

Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine

1 reference

12 December 2020

Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2

1 reference

12 December 2020

Effect of age, gender, and obesity on midazolam kinetics.

1 reference

12 December 2020

Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8

1 reference

12 December 2020

Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution

1 reference

12 December 2020

Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19.

1 reference

12 December 2020

The pharmacokinetics of dexfenfluramine in obese and non-obese subjects

1 reference

12 December 2020

Alterations in drug distribution and clearance due to obesity

1 reference

12 December 2020

Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion

1 reference

12 December 2020

Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test

1 reference

12 December 2020

Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia

1 reference

12 December 2020

Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis

1 reference

12 December 2020

Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans

1 reference

12 December 2020

Theophylline clearance: effect of marked obesity

1 reference

12 December 2020

Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans

1 reference

12 December 2020

Liver pathology in morbidly obese patients with and without diabetes

1 reference

12 December 2020

Cimetidine disposition in obesity

1 reference

12 December 2020

An overview of the pharmacology of intravenously administered ciprofloxacin

1 reference

12 December 2020

Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation

1 reference

12 December 2020

Disposition of enflurane in obese patients.

1 reference

12 December 2020

Functional and structural changes in the kidney in the early stages of obesity

1 reference

12 December 2020

Digoxin disposition in obesity: Clinical pharmacokinetic investigation

1 reference

12 December 2020

Gastric bypass in morbidly obese kidney transplant recipients

1 reference

12 December 2020

Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase

1 reference

12 December 2020

Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers

1 reference

12 December 2020

Renal disease in patients with massive obesity

1 reference

12 December 2020

Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment.

1 reference

12 December 2020

Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation.

1 reference

12 December 2020

The mechanism of renal clearance of cisplatin (cis-dichlorodiammine platinum ii) and its modification by furosemide and probenecid

1 reference

12 December 2020

Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women

1 reference

12 December 2020

CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles

1 reference

12 December 2020

Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study

1 reference

12 December 2020

Ibuprofen disposition in obese individuals

1 reference

12 December 2020

Pharmacokinetics of quinine in obesity

1 reference

12 December 2020

Effect of obesity on cyclosporine disposition

1 reference

12 December 2020

The role of cytochromes P-450 in cyclosporine metabolism

1 reference

12 December 2020

Intravenous ciprofloxacin disposition in obesity

1 reference

12 December 2020

Vancomycin dosing in morbidly obese patients

1 reference

12 December 2020

Hepatic cytochrome P-4503A (CYP3A) activity in the elderly

1 reference

12 December 2020

Effects of obesity on the cytochrome P450 enzyme system.

1 reference

12 December 2020

Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism

1 reference

12 December 2020

Increased enoxaparin dosing is required for obese children

1 reference

12 December 2020

Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism

1 reference

12 December 2020

Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption

1 reference

12 December 2020

Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects

1 reference

12 December 2020

Procainamide Disposition in Obesity

1 reference

12 December 2020

Verapamil pharmacodynamics and disposition in obese hypertensive patients

1 reference

12 December 2020

Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo)

1 reference

12 December 2020

Caffeine pharmacokinetics in obesity and following significant weight reduction

1 reference

12 December 2020

10.2165/11599410-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1004003598

0 references

Fatcat ID

release_ycyiguk4mre37fyuik67wpae7u

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ycyiguk4mre37fyuik67wpae7u

24 November 2022

mapped directly with Wikidata item

1 reference